Best in Biotech 21 Mar 2024
Eight CAR-T cell therapy companies you should know about
Discover eight promising biotech companies that are advancing their CAR T cell therapy candidates in the clinic.
Search Results for: CAR-T
In Depth 13 Dec 2023
Revolutionizing glioblastoma treatment: how CAR-T cell therapy could be used as a cure
Find out how CAR-T cell therapy, which has been so groundbreaking in treating blood cancers, could be used to cure glioblastoma.
More News! 4 Dec 2023
FDA CAR-T cell therapy warning: Are T cells malignant?
Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […]
In Depth 4 Oct 2023
CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off?
Riding on the success of CAR-T cell therapy, a breakthrough in the treatment of blood cancers, CAR-NK therapies are an emerging field in therapeutic research that aim to boost an even stronger immune response against cancer. What is CAR-NK cell therapy? Natural killer (NK) cells, like T cells, are white blood cells that are a […]
ADVERTISEMENT
News and Trends 4 Jul 2023
Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment
Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]
News and Trends 28 Feb 2023
Peter MacCallum Cancer Centre and Cartherics to work on CAR-T cell therapy for ovarian cancer
Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer. The clinical trial to be conducted by Peter Mac will be the first time a CAR-T cell therapy product […]
Streamlining CAR-T cell therapy manufacturing: a platform approach
Chimeric antigen receptor-T cell (CAR-T) therapy is an exciting treatment modality for blood cancers that do not respond to standard treatment. But manufacturing these CAR-T therapies brings challenges. How can life science companies overcome them to minimize costs and improve patient access? In patients with cancer for whom chemotherapy proves unsuccessful, CAR-T therapy may provide […]
News and Trends 9 Jan 2023
New biomarker for early prediction of response to CAR-T cell therapy
A MedUni Vienna research team in Austria has discovered a new highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step forward towards optimizing this promising therapy. The results of the study were recently published […]
News and Trends 22 Dec 2022
First CAR-T technology trial for patients with T-cell leukemia subtype authorized
The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with CAR-T technology for patients with a subtype of T-cell leukemia. The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This […]
News and Trends 8 Nov 2022
Collaboration to develop CAR-T cell therapy for cutaneous T-cell lymphoma
The Peter MacCallum Cancer Centre (Peter Mac) and Cartherics Pty Ltd (Cartherics) have entered into a collaborative development program agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL). “Patients with advanced stages of cutaneous T-cell lymphomas often have few treatment options left when their disease […]
News and Trends 27 Sep 2022
Bioheng Biotech has positive CAR-T cell therapy results published in academic journal
Positive results from a phase 1 clinical study of RD13-01, an anti-CD7 universal CAR-T therapy product, have been published in reputable academic journal, Cell Research. China-based Bioheng Biotech Co. Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy made the announcement today (September 27). The results published with the title of ‘CD7-targeted allogeneic CAR-T […]
News and Trends 19 Aug 2022
World’s first CAR-T for treatment of inflammatory disorders of the central nervous system approved in China
China’s National Medical Products (NMPA) has approved an investigational new drug application from IASO Bio for the new extended indication of neuromyelitis optica spectrum disorder (NMOSD). Neuromyelitis optica spectrum disorders previously known as Devic disease or neuromyelitis optica are inflammatory disorders of the central nervous system characterized by severe, immune-mediated demyelination and axonal damage predominantly targeting […]